All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the International Myeloma Foundation or HealthTree for Multiple Myeloma.

The Multiple Myeloma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Introducing

Now you can personalise
your Multiple Myeloma Hub experience!

Bookmark content to read later

Select your specific areas of interest

View content recommended for you

Find out more
  TRANSLATE

The Multiple Myeloma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Multiple Myeloma Hub cannot guarantee the accuracy of translated content. The Multiple Myeloma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
Visit:
ALL Hub

ALL Hub

AML Hub

AML Hub

GvHD Hub

GvHD Hub

Lupus Hub

Lupus Hub

Lymphoma Hub

Lymphoma Hub

MPN Hub

MPN Hub

PsOPsA Hub

PsOPsA Hub

LOADING
You're logged in! Click here any time to manage your account or log out.
LOADING
You're logged in! Click here any time to manage your account or log out.
Steering CommitteeAbout UsNewsletterContact
TypesTherapeuticsCongressesTrialsExpert OpinionsDRUG UPDATES
2021-07-12T11:00:17.000Z

Outcomes of triple-class exposed/refractory disease in real-world care: What is the current SoC?

By Marcia Rato, Joshua Reid, Zoe Brunn, Erika Roa
Featured
María-Victoria Mateos
Jul 12, 2021
Share:

Bookmark this article

During the ASCO 2021 Annual Meeting, the Multiple Myeloma Hub spoke with Maria Victoria Mateos, University Hospital of Salamanca, Salamanca, ES. We asked, what are the outcomes of triple-class exposed/refractory disease in real-world care: What is the current SoC?

Outcomes of triple-class exposed/refractory disease in real-world care: What is the current SoC?

Mateos discusses the results from LocoMMotion (NCT04035226), the first prospective efficacy and safety study of real-life SOC in patients with relapsed/refractory multiple myeloma (RRMM). 

 

More about...
ASCOASCO 2021EHAEHA 2021LocoMMotionRelapsed/refractory multiple myeloma

Your opinion matters

As a result of this content, I commit to reviewing the CARTITUDE clinical program to guide my understanding of cilta-cel in clinical practice.
28 votes - 4 days left ...

Related articles

Add bookmark

Findings from the MagnetisMM-1 trial of elranatamab in patients with RRMM: An update from ASH 2021

Elranatamab (PF-06863135) is a bispecific antibody (IgG2a) targeting the B-cell maturation antigen (BCMA) on multiple myeloma (MM) cells and CD3 on T...

Feb 18, 2022
Add bookmark

Findings from the MagnetisMM-1 trial of elranatamab in patients with RRMM: An update from ASH 2021

Elranatamab (PF-06863135) is a bispecific antibody (IgG2a) targeting the B-cell maturation antigen...

Feb 18, 2022
Add bookmark

Selinexor, pomalidomide, and dexamethasone for the treatment of relapsed/refractory multiple myeloma

Selinexor is an oral first-in-class selective inhibitor of nuclear export that inhibits exportin 1 (XPO1). XPO1 is responsible for the nuclear export...

Jul 16, 2021
Add bookmark

Selinexor, pomalidomide, and dexamethasone for the treatment of relapsed/refractory multiple myeloma

Selinexor is an oral first-in-class selective inhibitor of nuclear export that inhibits exportin 1...

Jul 16, 2021

Newsletter

Subscribe to get the best content related to multiple myeloma delivered to your inbox